Condition: Coronary Artery Disease · Antiplatelet Therapy · Minimally Invasive Coronary Revascularization Surgery · Sponsor: Cardiocentro Ticino
The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip. The study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand. Study Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications? Hypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure. This study will help doctors understand whether intraoperative cangrelor can improve patient safety and outcomes in minimally invasive heart surgery.
This description comes directly from the study's public registry record.
Marco Valgimigli, Prof Dr Med · +41 91 811 51 11 · marco.valgimigli@eoc.ch
Servizio di Ricerca Cardiovascolare Cardiocentro · +41 (0)91 811 53 04 · enrico.frigoli@eoc.ch
Always discuss trial participation with your own doctor first.
| Istituto Cardiocentro Ticino | Lugano, Ch/ti, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07514962